MedTrace Logo

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

NCT02500095 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-11-23

No results posted yet for this study

Summary

Background: Calorie restriction increases longevity in many species and attenuate the development of chronic disorders including type 2 diabetes, cardiovascular diseases and cancer. In mice reduced activity of insulin-like growth factor I (IGF-I) and/or insulin is associated with extended longevity. Growth hormone (GH) is the main regulator of IGF-I production, but the molecular mechanism whereby GH switches from IGF-I stimulation (protein anabolism) to fatty acid oxidation (fatty acid catabolism) as well as induction of insulin resistance during fasting remains enigmatic.

Hypotheses: The changes of the global set of metabolites, induction of insulin resistance, and the shift in metabolism from protein anabolism to lipolysis together with the potentially favorable effect of calorie restriction during fasting depend on preserved fasting-induced GH secretion.

Aim: The investigators wish to provide knowledge on changes in metabolites and shift in signaling pathways that take place at the transition to the fasting state among healthy overweight and obese subjects. Furthermore the investigators wish to determine the effect of GH on the adaption of the metabolism to a fasting state.

Conditions

  • Healthy

Interventions

OTHER

Fasting

72 hours of fasting

DRUG

Saline

Concomitant saline during fasting

DRUG

Pegvisomant

Concomitant Growth hormone receptor blockade with Pegvisomant during fasting

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jens Otto L. Jørgensen, Professor · Aarhus University / Aarhus University Hospital

  • Jens Otto L. Jørgensen, Professor · Aarhus University / Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500095 on ClinicalTrials.gov